20 articles
A comprehensive review reveals how obesity and aging converge through shared inflammatory biomarkers, accelerating disease risk in the elderly.
New review reveals GLP-1 receptor agonists may directly suppress chronic inflammation across multiple organ systems, far beyond their metabolic benefits.
New research reveals how gut bacteria, toxic fats, and immune responses create parallel inflammatory attacks on the liver.
New research reveals how obesity triggers chronic inflammation and how GLP-1 medications provide anti-inflammatory benefits independent of weight loss.
A new review links feline age-related obesity to SASP-driven chronic inflammation, offering translational insights for human metabolic disease.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
Knocking out BNIP3 in macrophages reduced adipose inflammation and improved insulin sensitivity in obese mice, revealing a new therapeutic target.
New research reveals how psoriasis increases inflammatory bowel disease risk by disrupting intestinal fat metabolism through immune cells.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
Scientists identify how a metabolic enzyme drives kidney inflammation in diabetes, opening doors for targeted therapies.
Multi-omic analysis reveals GLP-1 receptor agonists counter aging processes across multiple organ systems and biological pathways.
New research reveals how adrenaline from hypoglycemia causes prolonged inflammatory responses lasting up to seven days.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
Scientists discover how platelet-activating factor drives liver damage in obese women, revealing potential therapeutic targets.
New composite biomarker combining inflammation, nutrition, and immunity markers shows promise for cardiovascular risk assessment.
